Outlook Therapeutics, Inc.

OTLKReported to SECin USCIK 0001649989Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5
Form 4 lines at Outlook Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Lundquist Kevin MichaelChief Financial OfficerAwardnothing paid500,000 sharesSep 2, 2026Lundquist Kevin MichaelChief Financial Officernothing paidAward · Sep 2Award500,000Sep 2, 2026
Sukhtian Ghiath M.—Open-market buy$2,499,9992,525,252 sharesAug 14, 2026Sukhtian Ghiath M.$2,499,999Buy · Aug 14Open-market buy2,525,252Aug 14, 2026
Sukhtian Faisal Ghiath—Open-market buy$99,99695,398 sharesJul 29, 2026Sukhtian Faisal Ghiath$99,996Buy · Jul 29Open-market buy95,398Jul 29, 2026
KENYON LAWRENCE AChief Financial OfficerAwardnothing paid210,078 sharesJul 23, 2026KENYON LAWRENCE AChief Financial Officernothing paidAward · Jul 23Award210,078Jul 23, 2026
Jahr Robert CharlesChief Executive OfficerAwardnothing paid100,000 sharesJul 23, 2026Jahr Robert CharlesChief Executive Officernothing paidAward · Jul 23Award100,000Jul 23, 2026